Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:affects |
produces effects similar to heroin
|
| gptkbp:analytical_methods |
detected in blood tests
detected in urine tests requires specific assays for detection |
| gptkbp:application |
studied in pharmacology
|
| gptkbp:casnumber |
611-75-6
|
| gptkbp:chemical_formula |
C18 H21 NO3
|
| gptkbp:class |
gptkb:pharmaceuticals
|
| gptkbp:clinical_use |
pain management
opioid addiction treatment |
| gptkbp:composed_by |
acetylation of morphine
from morphine and acetic anhydride |
| gptkbp:discovery_year |
1970s
|
| gptkbp:dissolved |
soluble in water
|
| gptkbp:ecological_role |
metabolite
|
| https://www.w3.org/2000/01/rdf-schema#label |
6-monoacetylmorphine
|
| gptkbp:legal_status |
controlled substance in many countries
|
| gptkbp:marketed_as |
not commonly marketed as a standalone drug
|
| gptkbp:mass |
299.36 g/mol
|
| gptkbp:metabolism |
metabolized to morphine
|
| gptkbp:pharmacokinetics |
acts on opioid receptors
rapidly crosses the blood-brain barrier |
| gptkbp:previous_name |
(2 S)-N-[(2 R)-1-(4-hydroxyphenyl)propan-2-yl]-3-methoxy-3-oxopropanamide
|
| gptkbp:related_products |
heroin
morphine codeine |
| gptkbp:related_to |
heroin
|
| gptkbp:research_focus |
metabolic pathways
addiction mechanisms pain relief efficacy tolerance development opioid receptor interactions |
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety |
withdrawal symptoms
potential for abuse overdose risk |
| gptkbp:safety_features |
requires caution in use
|
| gptkbp:side_effect |
can cause dizziness
can cause nausea can cause confusion can cause constipation can cause euphoria can cause respiratory depression can cause sedation may lead to dependence |
| gptkbp:structure |
contains a morphinan skeleton
contains a phenolic hydroxyl group contains an acetyl group |
| gptkbp:toxicity |
can be addictive
|
| gptkbp:uses |
used in drug testing
|
| gptkbp:bfsParent |
gptkb:Heroin
|
| gptkbp:bfsLayer |
5
|